comment: the use of cdk 4/6 inhibitors now translates to a significant survival benefit in breas...
Published 5 years ago • 62 plays • Length 4:25Download video MP4
Download video MP3
Similar videos
-
20:19
expert discussion on cdk 4/6 inhibition in breast cancer
-
3:38
comment: cdk4/6 inhibitors in advanced breast cancer
-
5:16
cdk4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in hr-positive/her2-nega...
-
17:54
expert perspectives: cdk 4/6 inhibitors for er breast cancer: current data and clinical use
-
7:58
cdk 4/6 inhibitors: how are they used in metastatic breast cancer treatment?
-
2:19
cdk 4/6 inhibitors for patients with recurrent er /her2- breast cancer: 2023 best of breast
-
2:40
resistance to cdk4/6 inhibitors
-
30:52
esmo 2017: cdk4/6 inhibitors from a patient’s perspective
-
3:05
an overview of cdk 4/6 inhibitors for first line er advanced breast cancer
-
4:24
1l use of cdk4/6i et shows no clinically meaningful pfs compared to 2l use in hr , her2- abc
-
3:33
cdk 4/6 inhibitors in metastatic breast cancer
-
2:11
the use of frontline cdk4/6 inhibitors endocrine therapy in metastatic breast cancer
-
7:59
what are cdk 4/6 inhibitors for breast cancer?
-
29:09
interactive case: choosing and using cdk4/6 inhibitors in breast cancer - first-line therapy
-
3:21
benefits and challenges of cdk4/6 inhibitors
-
14:12
ongoing investigations and future applications of cdk 4/6 inhibitors
-
1:37
dr. han on the differences between cdk 4/6 inhibitors in er breast cancer
-
1:04
biomarkers to help predict response to cdk4/6 inhibitors
-
4:52
cdk4/6 inhibitors in hormone receptor-positive, her2-negative metastatic breast cancer